UBS Reiterates Buy Rating on Oruka Therapeutics
UBS keeps its buy rating for Oruka Therapeutics, setting a $130 price target, a 36.60% upside from the current price.
Key Points
- UBS analyst Michael Yee reiterated a buy rating on Oruka Therapeutics with a $130 price target as of July 1, 2026.
- UBS's $130 price target implies 36.60% upside from Oruka Therapeutics, Inc.'s ($ORKA) current $95.17 share price.
- Shares of Oruka Therapeutics traded at $95.17 on Wednesday, with the company having a market cap of approximately $5.74 billion.
- Insider Joana Goncalves made both purchases and sales in June, while UBS and BTIG analysts continue to support a buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, UBS analyst Michael Yee reiterated a buy rating on Oruka Therapeutics, Inc. (NasdaqGM: ORKA), setting a price target of $130. Shares traded at $95.17 on Wednesday. UBS's continued confidence in the stock suggests strong potential in Oruka's pipeline, focusing on novel treatments for psoriasis and other inflammatory conditions.
UBS vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Oruka Therapeutics
FMR LLC increased its holdings by 170,019 shares, resulting in a total of 7,431,403 shares valued at about $364.51 million, marking a 2.3% increase. Paradigm Biocapital Advisors LP also grew its stake significantly by 610,000 shares, a 35.7% increase, now holding 2,320,316 shares worth approximately $113.81 million. Meanwhile, BlackRock, Inc. slightly trimmed its position by 12,328 shares, leaving it with 3,527,087 shares valued at $173 million.
Oruka Therapeutics, Inc. Stock Up 4.4%
Shares of Oruka Therapeutics traded near $95.17 on Wednesday. The company has a market capitalization of approximately $5.74 billion. Oruka is not currently profitable, reflected in its forward P/E ratio of -38.65. The stock has shown significant volatility with a 52-week range between $10.97 and $97.78. The current ratios indicate strong liquidity, with a current ratio of 23.76 and a quick ratio of 23.38, while the debt-to-equity ratio stands at 0.37.
$ORKA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Oruka Therapeutics, Inc.
In recent insider activity, Joana Goncalves, the Chief Medical Officer, purchased 7,000 shares at an average price of $7.32 on June 15, 2026. On the same day, Goncalves sold 3,500 shares without a specified price. Arjun Agarwal, Senior Vice President of Finance, sold 1,587 shares at an average price of $80.95 on June 22, 2026, as part of a planned transaction.
Analysts Set New Price Targets
On July 1, 2026, UBS maintained its buy rating on Oruka Therapeutics with a price target of $130. BTIG reiterated its buy rating on May 14, 2026, with a target of $151. The consensus among analysts is a strong buy, with a mean price target of $142.17 based on 12 analyst opinions.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. Led by CEO Dr. Lawrence Otto Klein, the company focuses on developing monoclonal antibody therapeutics targeting psoriasis and other inflammatory and immunological conditions. Their leading projects include ORKA-001 and ORKA-002, which are in phase 2 trials for treating psoriasis and psoriatic arthritis.
Bottom Line
UBS's reiteration of a buy rating and a $130 price target underscores confidence in Oruka Therapeutics' potential, despite its current lack of profitability. With a robust pipeline and ongoing clinical trials, the company is a significant player in the biotechnology sector. Investors should note that analyst ratings and insider activities provide insights but reflect past decisions.
Get Oruka Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ORKA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.